Biomarin Pharmaceutical reported $194.62M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Acorda Therapeutics ACOR:US $ 25.44M 1.6M
Agios Pharmaceuticals AGIO:US $ 31.51M 13K
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Amgen AMGN:US $ 1.23B 197M
Bayer BAYN:GR 3.94B 346M
Biogen BIIB:US $ 634.9M 153M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Gilead Sciences GILD:US $ 1.08B 567M
Insmed INSM:US $ 56.75M 8.52M
Intercept Pharmaceuticals ICPT:US $ 50.01M 10.58M
IONIS PHARMACEUT IONS:US $ 34.13M 3.47M
Moderna Inc MRNA:US 268M 67M
Ptc Therapeutics PTCT:US $ 73.27M 13.28M
Puma Biotechnology PBYI:US $ 20.4M 2.06M
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M
Sangamo Biosciences SGMO:US $ 14.91M 1.18M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Seattle Genetics SGEN:US $ 174.22M 36.71M
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
United Therapeutics UTHR:US $ 79M 47.9M
Vertex Pharmaceuticals VRTX:US $ 215.2M 39.96M
YTE INCY:US $ 209.58M 16.62M